Janux Therapeutics Stock Probability of Future Stock Price Finishing Under 30.18
| JANX Stock | USD 55.17 0.97 1.73% |
Janux |
Janux Therapeutics Target Price Odds to finish below 30.18
The tendency of Janux Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 30.18 or more in 90 days |
| 55.17 | 90 days | 30.18 | near 1 |
Based on a normal probability distribution, the odds of Janux Therapeutics to drop to $ 30.18 or more in 90 days from now is near 1 (This Janux Therapeutics probability density function shows the probability of Janux Stock to fall within a particular range of prices over 90 days) . Probability of Janux Therapeutics price to stay between $ 30.18 and its current price of $55.17 at the end of the 90-day period is about 67.47 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.01 . This indicates Janux Therapeutics market returns are sensitive to returns on the market. As the market goes up or down, Janux Therapeutics is expected to follow. Additionally Janux Therapeutics has an alpha of 0.3358, implying that it can generate a 0.34 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Janux Therapeutics Price Density |
| Price |
Predictive Modules for Janux Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Janux Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Janux Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Janux Therapeutics is not an exception. The market had few large corrections towards the Janux Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Janux Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Janux Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | 1.01 | |
σ | Overall volatility | 6.06 | |
Ir | Information ratio | 0.05 |
Janux Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Janux Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Janux Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Janux Therapeutics is way too risky over 90 days horizon | |
| Janux Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 8.08 M. Net Loss for the year was (58.29 M) with loss before overhead, payroll, taxes, and interest of (44.83 M). | |
| Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15. | |
| Janux Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Meyer Andrew Hollman of 9880 shares of Janux Therapeutics at 20.24 subject to Rule 16b-3 |
Janux Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Janux Stock often depends not only on the future outlook of the current and potential Janux Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Janux Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 44 M | |
| Cash And Short Term Investments | 344 M |
Janux Therapeutics Technical Analysis
Janux Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Janux Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Janux Therapeutics. In general, you should focus on analyzing Janux Stock price patterns and their correlations with different microeconomic environments and drivers.
Janux Therapeutics Predictive Forecast Models
Janux Therapeutics' time-series forecasting models is one of many Janux Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Janux Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Janux Therapeutics
Checking the ongoing alerts about Janux Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Janux Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Janux Therapeutics is way too risky over 90 days horizon | |
| Janux Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 8.08 M. Net Loss for the year was (58.29 M) with loss before overhead, payroll, taxes, and interest of (44.83 M). | |
| Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15. | |
| Janux Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Meyer Andrew Hollman of 9880 shares of Janux Therapeutics at 20.24 subject to Rule 16b-3 |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.